Tyrus Capital S.A.M. bought a new stake in C.R. Bard, Inc. (NYSE:BCR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 65,000 shares of the medical instruments supplier’s stock, valued at approximately $20,547,000. C.R. Bard makes up about 1.6% of Tyrus Capital S.A.M.’s investment portfolio, making the stock its 11th largest position. Tyrus Capital S.A.M. owned approximately 0.09% of C.R. Bard as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of the business. SRS Capital Advisors Inc. increased its position in shares of C.R. Bard by 0.7% during the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after acquiring an additional 4 shares in the last quarter. Alps Advisors Inc. increased its position in shares of C.R. Bard by 0.3% during the second quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock worth $607,000 after acquiring an additional 5 shares in the last quarter. KCM Investment Advisors LLC increased its position in shares of C.R. Bard by 0.5% during the second quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 10 shares in the last quarter. Parallel Advisors LLC increased its position in shares of C.R. Bard by 2.8% during the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after acquiring an additional 14 shares in the last quarter. Finally, Blair William & Co. IL increased its position in shares of C.R. Bard by 0.9% during the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock worth $865,000 after acquiring an additional 30 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Tyrus Capital S.A.M. Invests $20.55 Million in C.R. Bard, Inc. (BCR) Stock” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/tyrus-capital-s-a-m-invests-20-55-million-in-c-r-bard-inc-bcr-stock/1613058.html.

Shares of C.R. Bard, Inc. (BCR) traded up 0.15% on Friday, reaching $321.44. 120,574 shares of the company traded hands. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $324.58. The firm has a 50-day moving average price of $319.92 and a 200 day moving average price of $304.54. The company has a market capitalization of $23.36 billion, a PE ratio of 42.20 and a beta of 0.58.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. C.R. Bard’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.54 EPS. Equities analysts forecast that C.R. Bard, Inc. will post $11.81 EPS for the current fiscal year.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sharon M. Luboff sold 30,252 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $320.00, for a total transaction of $9,680,640.00. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

Several brokerages have recently issued reports on BCR. Jefferies Group LLC reissued a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. BidaskClub downgraded shares of C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $292.00.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.